National Heart Lung and Blood Institute

PTC Therapeutics cuts workforce 18%

Thursday, March 24, 2016

PTC Therapeutics is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S. This reduction is part of PTC’s program intended to optimally manage operating expenses following its recent setback related to the Refuse to File letter received from the FDA for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). 

[Read More]

NIH Common Fund launches biomed programs

Monday, October 5, 2015

The NIH Common Fund has awarded more than $54 million in fiscal year 2015 to launch projects in four broad scientific areas: the Glycoscience Program, the 4D Nucleome Program, the Gabriella Miller Kids First Research Program and the Science of Behavior Change Program. The Common Fund planning process identifies major challenges that impede progress in research and emerging areas of science that promise to change the way people think about health and disease or the way prevention or treatment is approached. Common Fund programs that emerge are goal-driven, with deliverables expected within a five to 10 year period. The 2015 awards represented first-year funding of a multiyear program.

[Read More]

NIH awards $9M to speed development of health technologies

Monday, March 30, 2015

The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.

[Read More]

Heptares expands board of directors

Thursday, January 8, 2015

Heptares Therapeutics, a clinical-stage GPCR structure-guided drug discovery and development company, has appointed Atul Pande and Roberto Solari to its board of directors. Pande and Solari bring significant industry experience in the discovery and validation of drug targets and the subsequent development of novel medicines.

[Read More]

PCORI, NIH request applications to study blood pressure control

Wednesday, December 10, 2014

The NIH, as part of a research partnership with the Patient-Centered Outcomes Research Institute (PCORI), has issued a request for applications (RFA) to study how to improve blood pressure control among populations at highest risk for suffering hypertension-related strokes, heart attacks and other cardiovascular events. PCORI is a Wash. D.C.-based independent nonprofit organization authorized by Congress.

[Read More]

NIH awards $64M for the understanding of cell pathways, development of new therapies

Tuesday, September 16, 2014

Building on a successful three-year pilot project, the NIH has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures (LINCS).  Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies for many diseases.

[Read More]

Study: $260M spent on Women’ Health Initiative trial has saved $37B in healthcare costs over 10 years

Tuesday, May 6, 2014

Critics opposed to hefty government research spending may think twice after learning that a 15-year, $260 million federally funded study—known as the Women’s Health Initiative (WHI) estrogen plus progestin clinical trial—showed changes in medical practice stemming from the trial provided a net economic return of $37.1 billion over a 10-year period—or about $140 on every federal dollar invested in the trial.

[Read More]